Season 9 · Episode 3
S9 Ep3: FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC
OncLive® On Air · OncLive® On Air
June 15, 202312m 18s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr Armstrong discusses the FDA approval of olaparib plus abiraterone in patients with BRCA-mutated mCRPC, key efficacy and safety data from the PROpel trial, and where the field of prostate cancer research may be headed in the future.